Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Observational Study Finds Sanofi’s Diabetes Drug Lowers Incidence of Hypoglycemia


According to the researchers – who presented at the Endocrine Society 2017 Annual Meeting – diabetic patients taking Toujeo experienced fewer hypoglycemic events, without loss of blood sugar control.

Share this!

April 4, 2017 | by Sarah Hand, M.Sc.

Data from a recent real-world observational study has found that that Sanofi’s type 2 diabetes drug, Toujeo (insulin glargine 300 Units/mL), was associated with a lower risk of hypoglycemia, compared to other basal insulins. According to the researchers – who presented at the Endocrine Society 2017 Annual Meeting – diabetic patients taking Toujeo experienced fewer hypoglycemic events, without loss of blood sugar control.

The observational study – DELIVER 1 – analyzed the electronic medical records for nearly 1,900 type 2 diabetic patients. For the purposes of comparative analysis, patients were equally split into two cohorts: patients that switched from basal insulin to Toujeo, and patients that switched from one basal insulin to another.

Using data collected one year before the medication switch, and six months after, the researchers compared the average change in blood sugar levels, occurrence of hypoglycemia, and the incidence of hypoglycemia-related inpatient or emergency room visits. Diabetic patients who switched from basal insulin to Toujeo showed fewer hypoglycemic events, compared those who switched to another basal insulin.

What’s more, the reduced rate of hypoglycemic events was not associated with a compromise in blood sugar control in patients taking Toujeo. Patients taking Toujeo also experienced a nearly 50 percent reduction in inpatient or emergency room visits associated with hypoglycemic events.

“These results increase the body of evidence on the use of Toujeo in people with type 2 diabetes from observational studies,” said Riccardo Perfetti, Head of Global Diabetes Medical Team, ‎Sanofi. “While randomized clinical trials provide the highest level of evidence, comparative data from real-world observational studies can be relevant for payors and other organizations evaluating how findings from clinical trials can translate into routine clinical practice.”

Toujeo was approved by the US Food and Drug Administration (FDA) over two years ago, in February of 2015. In the fourth quarter of 2016, Toujeo sales totaled €238 million, with €169 million generated in the US market alone.

“Sanofi is committed to going beyond traditional models to conduct further studies to assess Toujeo, combining the broad populations, and type of interaction between healthcare professionals and patients seen in routine care with the rigorous methodology of clinical trials,” said Perfetti. “The randomized Real Life Study program will provide further evidence that directly reflects Toujeo's performance in standard clinical practice.”

Keywords:  Observational Study, Diabetes, Insulin


Share this with your colleagues!

Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News

New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News

Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub


Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases

Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects

Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance

Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned

Copyright © 2016-2017 Honeycomb Worldwide Inc.